Use of Recombinant Vaccinia-Rabies Glycoprotein Virus for Oral Vaccination of Wildlife Against Rabies: Innocuity to Several Non-Target Bait Consuming Species

Brochier, Bernard; Blancou, Jean; Thomas, Isabelle; Languet, B.; Artois, Marc; Kiény, Marie-Paule; Lecocq, Jean‐Pierre; Costy, F.; Desmettre, P; Chappuis, G.; Pastoret, Paul-Pierre

doi:10.7589/0090-3558-25.4.540

Cited by 74 publications

(44 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Oral vaccination significantly slowed pathologic progression of disease in our animals over a 5-mo period and thus is a promising candidate for use in field. Oral vaccination of wildlife is a management tool that has been successfully implemented in Europe to control rabies in red fox (Vulpes vulpes; Brochier et al, 1989) and is currently being used in the United States to manage the disease in raccoons (Procyon lotor). Oral BCG vaccination of wildlife reservoirs of bovine tuberculosis is being extensively researched for application in many countries, including New Zealand, United Kingdom, Ireland, United States, and South Africa.…”

Section: Discussionmentioning

confidence: 99%

“EFFICACY OF ORAL AND PARENTERAL ROUTES OF MYCOBACTERIUM BOVIS BACILLE CALMETTE-GUERIN VACCINATION AGAINST EXPERIMENTAL BOVINE TUBERCULOSIS IN WHITE-TAILED DEER (ODOCOILEUS VIRGINIANUS): A FEASIBILITY STUDY.”

2009

Journal of Wildlife Diseases

View full text Add to dashboard Cite

We investigated the efficacy of oral and parenteral Mycobacterium bovis bacille Calmette-Guerin Danish strain 1331 (BCG) in its ability to protect white-tailed deer (Odocoileus virginianus) against disease caused by M. bovis infection. Twenty-two white-tailed deer were divided into four groups. One group (n55) received 10 9 colony-forming units (cfu) BCG via a lipid-formulated oral bait; one group (n55) received 10 9 cfu BCG in culture directly to the oropharynx, one group (n56) was vaccinated with 10 6 cfu BCG subcutaneously, and one group served as a control and received culture media directly to the oropharynx (n56). All animals were challenged 3 mo after vaccination. Five months postchallenge the animals were examined for lesions. Results indicate that both oral forms of BCG and parenterally administerd BCG offered significant protection against M. bovis challenge as compared to controls. This study suggests that oral BCG vaccination may be a feasible means of controlling bovine tuberculosis in wild whitetailed deer populations.

show abstract

Section: Discussionmentioning

confidence: 99%

“EFFICACY OF ORAL AND PARENTERAL ROUTES OF MYCOBACTERIUM BOVIS BACILLE CALMETTE-GUERIN VACCINATION AGAINST EXPERIMENTAL BOVINE TUBERCULOSIS IN WHITE-TAILED DEER (ODOCOILEUS VIRGINIANUS): A FEASIBILITY STUDY.”

2009

Journal of Wildlife Diseases

View full text Add to dashboard Cite

show abstract

“…From the human safety perspective, the proven safety record of the Raboral TM vaccine sets a precedent for vaccinia, with only two reported cases of human infection (both due to mishandling of the vaccine) from over 100 million doses administered for rabies control across two continents over 20 years (CDC Report 2009). From the veterinary safety perspective, there are no reports of sustained vaccinia infection nor of patency in over 30 non-target animal and bird species tested (reviewed by Brochier et al 1989;Artois et al 1990;Hanlon et al 1997). However, evidence of immune recognition (which implies a self-limiting infection and minimal viral replication) exists in non-target species.…”

Section: Recombinant Poxvirusesmentioning

confidence: 99%

“…However, evidence of immune recognition (which implies a self-limiting infection and minimal viral replication) exists in non-target species. Brochier et al (1989) reported safety-testing of a recombinant vaccinia construct as an oral inoculum in non-target European wildlife, with seroconversion in !50% of all mammals but no reactivity in birds, while Artois et al (1990) reported seroconversion to the same construct in !75% of North American mammals.…”

Section: Recombinant Poxvirusesmentioning

confidence: 99%

Could recombinant technology facilitate the realisation of a fertility-control vaccine for possums?

Cross

Zheng

Duckworth

et al. 2011

New Zealand Journal of Zoology

View full text Add to dashboard Cite

While lethal control remains the primary tool for possum control in New Zealand, there has been substantial research effort over the last decade into controlling possum populations by reducing the animals' breeding potential. In particular, the potential of immunological control to reduce fertility has been investigated, whereby the possums' immune system is induced to react against its reproductive system, in order to block or destroy key components of the reproductive process. Two of the most targeted key components have been the blocking of circulating hormones (e.g. gonadotrophin-releasing hormone) and the inhibition of functional egg surface proteins (e.g. zona pellucida). While some success has been achieved for each approach, three main obstacles remain to the development of a working fertility-control vaccine for possums: first, ensuring that the vaccine remains efficacious in oral-delivery formulation; second, ensuring sufficient levels of fertility reduction; and third, ensuring that the induced immune response is sustained for a duration sufficient for long-term suppression of reproduction. The use of a genetically modified recombinant organism (parasite, bacterium or virus) to deliver a fertility-control vaccine could satisfy these requirements. A strong precedent for this approach has been set already in wildlife biology, namely the oral rabies vaccine, which is based on a recombinant vaccinia virus and which has been used successfully for the last 25 years as a disease-eliminating vaccine in mesocarnivores in Europe and North America. This review outlines the different forms and examples of recombinant organisms with potential for engineering into recombinant fertilitycontrol vaccines to reduce possum reproduction; non-transmissible agents or fully-transmissible vectors are discussed, with shortcomings and benefits outlined for each.

show abstract

“…It, thus, remains an important problem for public health [8,35]. Poor vaccination coverage, sometimes with inferior quality vaccines that fail to maintain persistent levels of neutralizing antibodies, in addition to the difficulty in re-locating stray dogs for booster vaccinations, suggests that an inexpensive rabies vaccine eliciting a long-term protection after a one-time vaccination might facilitate the control of rabies in developing countries [23].…”

Section: Introductionmentioning

confidence: 99%

Intradermal DNA vaccination in ear pinnae is an efficient route to protect cats against rabies virus

et al. 2008

View full text Add to dashboard Cite

-A DNA vaccine against rabies (pGQH) was administrated to cats in order to examine different administration routes. Four groups of three cats each were inoculated with pGQH as follows: group A, intramuscularly (IM), 100 µg; group B, intranasally (IN), 100 µg; group C, intradermally into ear pinnae (ID-EP), 100 µg, and group D, IM, 200 µL of phosphate buffer solution (PBS) alone (control group). Blood was drawn on days 0, 30, 60, 90, 120, 150, and 180. Groups A, B, and C received a booster on day 30. At day 200 all animals were challenged. A passive transfer of cat sera, as well as a viral challenge, was performed in mice. The results displayed that neutralizing antibody titers were higher in cats of group C (ID-EP) showing high early titers (> 2 IU) and the highest titer was on day 120 (> 14 IU). In group B (IN), two out of three cats seroconverted on day 30 (> 0.5 IU), the third cat seroconverted until day 60 (> 0.5 IU). In contrast, the lowest levels of neutralizing antibodies were detected in group A (IM). The control group showed no anti-rabies antibodies. Groups A (IM) and D (control) succumbed after lethal challenge. All animals from the ID-EP group (C) survived, only one individual from the IN (B) group died. Mice that received cat sera from ID-EP, IM, and IN groups survived and were protected (30/30 survivors). Mice groups that received pre-immunization sera from cats were not protected (0/30 survivors). This study demonstrates that pGQH immunization was successful when it was administrated ID-EP, and acceptable through the IN route. The IM route, however, was not effective in cats. For vaccination, the IN route seems attractive due to its accessibility for application, but it seems to activate seroconversion slowly. The best route to promote anti-rabies antibody titers was the ID-EP route. This practical and efficient route should be further studied.rabies / DNA vaccine / intradermal into ear pinna / intranasal / cats

show abstract

Use of Recombinant Vaccinia-Rabies Glycoprotein Virus for Oral Vaccination of Wildlife Against Rabies: Innocuity to Several Non-Target Bait Consuming Species

Cited by 74 publications

References 9 publications

“EFFICACY OF ORAL AND PARENTERAL ROUTES OF MYCOBACTERIUM BOVIS BACILLE CALMETTE-GUERIN VACCINATION AGAINST EXPERIMENTAL BOVINE TUBERCULOSIS IN WHITE-TAILED DEER (ODOCOILEUS VIRGINIANUS): A FEASIBILITY STUDY.”

“EFFICACY OF ORAL AND PARENTERAL ROUTES OF MYCOBACTERIUM BOVIS BACILLE CALMETTE-GUERIN VACCINATION AGAINST EXPERIMENTAL BOVINE TUBERCULOSIS IN WHITE-TAILED DEER (ODOCOILEUS VIRGINIANUS): A FEASIBILITY STUDY.”

Could recombinant technology facilitate the realisation of a fertility-control vaccine for possums?

Intradermal DNA vaccination in ear pinnae is an efficient route to protect cats against rabies virus

Contact Info

Product

Resources

About